Avacta boosted by COVID-19 reagent developments

By
1 mins. to read
Avacta boosted by COVID-19 reagent developments

AIM-listed biotechnology firm Avacta Group (LON:AVCT) watched its shares surge 33.92% to 142.62p (as of 13:35 BST) after reagents developed for use in COVID-19 testing were found to block part of the viral infection pathway. The company is seeking a partner to develop a neutralising therapy as fast as possible.

CEO Dr. Alastair Smith commented: “This is a very exciting development in the COVID-19 programme. It only took four weeks to generate more than fifty Affimer reagents that bind the SARS-COV-2 virus spike protein and amongst those we now know that there are neutralising Affimers that block the interaction with a key human cell surface receptor, raising the potential for a therapy to prevent infection.

“Recently GSK invested $250 million in Vir Biotechnology Inc3 to develop potential antibody treatments for COVID-19 by selecting antibodies from recovered patients, and AstraZeneca also recently announced that it would start a programme to find new monoclonal antibodies that block the spike/ACE2 interaction4.

“There is significant potential for a therapy that could help prevent infection and limit the progression of the disease, providing immediate benefit to patients. With a large and well-resourced partner, a neutralising Affimer therapy could potentially be developed more quickly than a vaccine and we believe that the likelihood of success would be high.

“I look forward to updating the market further on this and on the development of a COVID-19 antigen rapid saliva test with Cytiva which continues apace“.

Take part in our poll

We are reviewing our content and would value you feedback. What types of content would you like to see more of?


Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *